{"version ": "BioASQ6b", "data": [{"title": "BioASQ6b", "paragraphs": [{"qas": [{"id": "54e25eaaae9738404b000017_001", "question": "Is the protein Papilin secreted?", "is_impossible": false, "answers": "yes"}], "context": "Using expression analysis, we identify three genes that are transcriptionally regulated by HLH-2: the protocadherin cdh-3, and two genes encoding secreted extracellular matrix proteins, mig-6/papilin and him-4/hemicentin. "}, {"qas": [{"id": "54e25eaaae9738404b000017_002", "question": "Is the protein Papilin secreted?", "is_impossible": false, "answers": "yes"}], "context": "We found that mig-6 encodes long (MIG-6L) and short (MIG-6S) isoforms of the extracellular matrix protein papilin, each required for distinct aspects of DTC migration. Both MIG-6 isoforms have a predicted N-terminal papilin cassette"}, {"qas": [{"id": "54e25eaaae9738404b000017_003", "question": "Is the protein Papilin secreted?", "is_impossible": false, "answers": "yes"}], "context": "apilins are homologous, secreted extracellular matrix proteins which share a common order of protein domains. "}, {"qas": [{"id": "54e25eaaae9738404b000017_004", "question": "Is the protein Papilin secreted?", "is_impossible": false, "answers": "yes"}], "context": "The TSR superfamily is a diverse family of extracellular matrix and transmembrane proteins, many of which have functions related to regulating matrix organization, cell-cell interactions and cell guidance. This review samples some of the contemporary literature regarding TSR superfamily members (e.g. F-spondin, UNC-5, ADAMTS, papilin, and TRAP) where specific functions are assigned to the TSR domains."}, {"qas": [{"id": "54e25eaaae9738404b000017_005", "question": "Is the protein Papilin secreted?", "is_impossible": false, "answers": "yes"}], "context": "Papilins are extracellular matrix proteins "}, {"qas": [{"id": "54e25eaaae9738404b000017_006", "question": "Is the protein Papilin secreted?", "is_impossible": false, "answers": "yes"}], "context": "Papilin is an extracellular matrix glycoprotein "}, {"qas": [{"id": "54e25eaaae9738404b000017_007", "question": "Is the protein Papilin secreted?", "is_impossible": false, "answers": "yes"}], "context": " Collagen IV, laminin, glutactin, papilin, and other extracellular matrix proteins were made primarily by hemocytes and were secreted into the medium. "}, {"qas": [{"id": "54e25eaaae9738404b000017_008", "question": "Is the protein Papilin secreted?", "is_impossible": false, "answers": "yes"}], "context": "A sulfated glycoprotein was isolated from the culture media of Drosophila Kc cells and named papilin."}, {"qas": [{"id": "535d292a9a4572de6f000003_001", "question": "Are long non coding RNAs spliced?", "is_impossible": false, "answers": "yes"}], "context": "Our analyses indicate that lncRNAs are generated through pathways similar to that of protein-coding genes, with similar histone-modification profiles, splicing signals, and exon/intron lengths."}, {"qas": [{"id": "535d292a9a4572de6f000003_002", "question": "Are long non coding RNAs spliced?", "is_impossible": false, "answers": "yes"}], "context": "For alternative exons and long noncoding RNAs, splicing tends to occur later, and the latter might remain unspliced in some cases."}, {"qas": [{"id": "535d292a9a4572de6f000003_003", "question": "Are long non coding RNAs spliced?", "is_impossible": false, "answers": "yes"}], "context": "bosome-mapping data to identify lncRNAs of Caenorhabditis elegans. We found 170 long intervening ncRNAs (lincRNAs), which had single- or multiexonic structures that did not overlap protein-coding transcripts, and about sixty antisense lncRNAs (ancRNAs), which were complementary to protein-coding transcripts"}, {"qas": [{"id": "535d292a9a4572de6f000003_004", "question": "Are long non coding RNAs spliced?", "is_impossible": false, "answers": "yes"}], "context": "We introduce an approach to predict spliced lncRNAs in vertebrate genomes combining comparative genomics and machine learning."}, {"qas": [{"id": "535d292a9a4572de6f000003_005", "question": "Are long non coding RNAs spliced?", "is_impossible": false, "answers": "yes"}], "context": "Owing to similar alternative splicing pattern to mRNAs, the concept of lncRNA genes was put forward to help systematic understanding of lncRNAs. "}, {"qas": [{"id": "535d292a9a4572de6f000003_006", "question": "Are long non coding RNAs spliced?", "is_impossible": false, "answers": "yes"}], "context": "Our synthesis of recent studies suggests that neither size, presence of a poly-A tail, splicing, direction of transcription, nor strand specificity are of importance to lncRNA function."}, {"qas": [{"id": "55262a9787ecba3764000009_001", "question": "Is RANKL secreted from the cells?", "is_impossible": false, "answers": "yes"}], "context": "Osteoprotegerin (OPG) is a soluble secreted factor that acts as a decoy receptor for receptor activator of NF-\u03baB ligand (RANKL) "}, {"qas": [{"id": "55262a9787ecba3764000009_002", "question": "Is RANKL secreted from the cells?", "is_impossible": false, "answers": "yes"}], "context": "Osteoprotegerin (OPG) is a secreted glycoprotein and a member of the tumor necrosis factor receptor superfamily. It usually functions in bone remodeling, by inhibiting osteoclastogenesis through interaction with a receptor activator of the nuclear factor \u03baB (RANKL)."}, {"qas": [{"id": "55262a9787ecba3764000009_003", "question": "Is RANKL secreted from the cells?", "is_impossible": false, "answers": "yes"}], "context": "e RANKL/OPG ratio secreted by osteoblasts increased and RANK expression by osteoclasts increased, leading to increased osteoclastogenesis"}, {"qas": [{"id": "55262a9787ecba3764000009_004", "question": "Is RANKL secreted from the cells?", "is_impossible": false, "answers": "yes"}], "context": "Osteoprotegerin (OPG) is an essential secreted protein in bone turnover due to its role as a decoy receptor for the Receptor Activator of Nuclear Factor-kB ligand (RANKL) in the osteoclasts, thus inhibiting their differentiation"}, {"qas": [{"id": "55262a9787ecba3764000009_005", "question": "Is RANKL secreted from the cells?", "is_impossible": false, "answers": "yes"}], "context": "We identify a TNFSF11 transcript variant that extends the originally identified transcript encoding secreted RANKL."}, {"qas": [{"id": "55262a9787ecba3764000009_006", "question": "Is RANKL secreted from the cells?", "is_impossible": false, "answers": "yes"}], "context": "Activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL."}, {"qas": [{"id": "55262a9787ecba3764000009_007", "question": "Is RANKL secreted from the cells?", "is_impossible": false, "answers": "yes"}], "context": "OPG, on the other hand, is secreted by osteoblast as a decoy receptor for RANKL, prevents RANKL from binding to RANK and thus prevents bone resorption"}, {"qas": [{"id": "55262a9787ecba3764000009_008", "question": "Is RANKL secreted from the cells?", "is_impossible": false, "answers": "yes"}], "context": "Receptor activator of nuclear factor \u03baB ligand (RANKL) and osteoprotegerin (OPG) are cytokines predominantly secreted by osteoblasts and play a central role in differentiation and functional activation of osteoclasts"}, {"qas": [{"id": "55262a9787ecba3764000009_009", "question": "Is RANKL secreted from the cells?", "is_impossible": false, "answers": "yes"}], "context": "Although B. abortus-activated T cells actively secreted the pro-osteoclastogenic cytokines RANKL and IL-17, osteoclastogenesis depended on IL-17, because osteoclast generation induced by Brucella-activated T cells was completely abrogated when these cells were cultured with BMMs from IL-17 receptor knockout mice. "}, {"qas": [{"id": "55262a9787ecba3764000009_010", "question": "Is RANKL secreted from the cells?", "is_impossible": false, "answers": "yes"}], "context": " osteoclastogenesis and bone destruction in autoimmune arthritis. We isolated human fibroblasts from RA, pyrophosphate arthropathy (PPA) and osteoarthritis (OA) patients and analyzed their RANKL/OPG expression profile and the capacity of their secreted factors to induce osteoclastogenesis."}, {"qas": [{"id": "55262a9787ecba3764000009_011", "question": "Is RANKL secreted from the cells?", "is_impossible": false, "answers": "yes"}], "context": "Osteoprotegerin (OPG) and receptor activator of nuclear factor \u03baB ligand (RANKL) are cytokines predominantly secreted by osteoblasts and play critical roles in the differentiation and function of osteoclasts. "}, {"qas": [{"id": "52bf1db603868f1b06000011_001", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": "Denosumab is a RANK-ligand antibody that was approved by the FDA in 2010 for the prevention of skeletal fractures in patients with bone metastases from solid tumors."}, {"qas": [{"id": "52bf1db603868f1b06000011_002", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": " The authors present the imaging findings and technical report of an attempted percutaneous vertebroplasty in the only patient found to be actively under treatment with denosumab after a retrospective review of the databank of patients with pathological fractures referred to the Department Radiology of the Ohio State University for percutaneous vertebroplasty (a total sample of 20 patients) since the FDA approval of denosumab (November 2010) until June of 2013 (a 30-month period)."}, {"qas": [{"id": "52bf1db603868f1b06000011_003", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": "On the basis of this data, the FDA approved denosumab for the treatment of patients whose GCTB is unresectable, or when surgery is likely to result in severe morbidity."}, {"qas": [{"id": "52bf1db603868f1b06000011_004", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": "Denosumab (Prolia\u00ae) is a fully human monoclonal antibody for RANKL, which selectively inhibits osteoclastogenesis, being recently approved for the treatment of postmenopausal osteoporosis in women at a high or increased risk of fracture by the FDA in the United Sates and by the European Medicines Agency in Europe since June 2010."}, {"qas": [{"id": "52bf1db603868f1b06000011_005", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": "Recent phase II clinical trials with denosumab in skeletally mature adolescents over age 12 years and adults with GCTB, have shown both safety and efficacy, leading to its accelerated US FDA approval on 13 June 2013. "}, {"qas": [{"id": "52bf1db603868f1b06000011_006", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": "Zoledronic acid (ZA), an intravenously administered bisphosphonate, and Denosumab, a subcutaneously administered inhibitor of nuclear factor B ligand (RANKL), have already been approved by Food and Drug Administration (FDA) for their use in treatment of bone metastases."}, {"qas": [{"id": "52bf1db603868f1b06000011_007", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": "These results led to the approval of denosumab by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), for the prevention of SREs in adults with bone metastases from solid tumors, including breast cancer."}, {"qas": [{"id": "52bf1db603868f1b06000011_008", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": "Alendronate, risedronate, zoledronic acid, denosumab, and teriparatide are Food and Drug Administration (FDA)-approved therapeutic options. "}, {"qas": [{"id": "52bf1db603868f1b06000011_009", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": "Several of these therapies have recently been approved by the FDA to treat bone cancer pain (bisphosphonates, denosumab) and others are currently being evaluated in human clinical trials (tanezumab)."}, {"qas": [{"id": "52bf1db603868f1b06000011_010", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": "A fourth agent, denosumab (bone targeted therapy) was also recently approved by the FDA for patients with bone metastasis after showing a reduction in the occurrence of skeletal-related events. "}, {"qas": [{"id": "52bf1db603868f1b06000011_011", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": "AHRQ published an updated review in March 2012 that summarized the benefits and risks of osteoporosis medications in treatment and prevention of osteoporosis, including bisphosphonates (aledronate, risedronate, ibandronate, zoledronic acid), parathyroid hormone, teriparatide, calcitonin, estrogens (for prevention in postmenopausal women), selective estrogen receptor modulators (raloxifene), and denosumab(approved by the FDA in 2010). "}, {"qas": [{"id": "52bf1db603868f1b06000011_012", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": "Four new drugs have received U.S. Food and Drug Administration (FDA)-approval in 2010 and 2011: sipuleucel-T, an immunotherapeutic agent; cabazitaxel, a novel microtubule inhibitor; abiraterone acetate, a new androgen biosynthesis inhibitor; and denosumab, a bone-targeting agent. "}, {"qas": [{"id": "52bf1db603868f1b06000011_013", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": "Recently, the US FDA and the EMA approved denosumab (a fully human monoclonal antibody) to treat skeletal-related events in bone-metastatic prostate cancer."}, {"qas": [{"id": "52bf1db603868f1b06000011_014", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": "In addition to these new and emerging therapeutic agents, denosumab was approved for the prevention of skeletal complications in patients with bone metastases due to solid tumor malignancies, providing an alternative to zoledronic acid. "}, {"qas": [{"id": "52bf1db603868f1b06000011_015", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": "Recently, denosumab was FDA-approved for prevention of SREs in patients with bone metastases from solid tumors. "}, {"qas": [{"id": "52bf1db603868f1b06000011_016", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": "In the 2010s to date, an additional 3 antibodies (denosumab, belimumab, ipilimumab) have been approved and one antibody-drug conjugate (brentuximab vedotin) is undergoing regulatory review and may be approved in the US by August 30, 2011."}, {"qas": [{"id": "52bf1db603868f1b06000011_017", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": "We also review the evidence supporting the FDA's approval of denosumab (bone-targeted therapy) as a treatment option for men with CRPC and bony metastases. "}, {"qas": [{"id": "52bf1db603868f1b06000011_018", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": " It has been approved for clinical use by the FDA in the US and by the European Medicines Agency in Europe since June 2010 (trade name Prolia(\u2122), Amgen, Thousand Oaks, CA, USA). "}, {"qas": [{"id": "52bf1db603868f1b06000011_019", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": "The fully human monoclonal antibody denosumab (Prolia(\u00ae)) has been recently approved by the European Medical Agency (EMEA) and the Food and Drug Administration (FDA) for the treatment of postmenopausal osteoporosis. "}, {"qas": [{"id": "52bf1db603868f1b06000011_020", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": "Raloxifene and denosumab are only FDA approved for postmenopausal osteoporosis."}, {"qas": [{"id": "52bf1db603868f1b06000011_021", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": "The new antiresorptive drug, denosumab, although FDA-approved only for postmenopausal women, has been shown in a study of men on ADT to increase bone density in spine, hip, and forearm and decrease vertebral fractures on x-ray. "}, {"qas": [{"id": "52bf1db603868f1b06000011_022", "question": "Has Denosumab (Prolia) been approved by FDA?", "is_impossible": false, "answers": "yes"}], "context": " Since then, an additional six human mAbs have received FDA approval: panitumumab, golimumab, canakinumab, ustekinumab, ofatumumab and denosumab. "}, {"qas": [{"id": "5313b049e3eabad021000013_001", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "Herceptin is widely used in treating Her2-overexpressing breast cancer. However, the application of Herceptin in prostate cancer is still controversial."}, {"qas": [{"id": "5313b049e3eabad021000013_002", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "Our data demonstrate that Re-188-labeled Herceptin effectively inhibited the growth of DU145 cells compared to the Herceptin- and Re-188-treated cohorts. This implies that targeting Her2 by both radio- and immuno- therapy might be a potential strategy for treating patients with androgen-independent prostate cancer."}, {"qas": [{"id": "5313b049e3eabad021000013_003", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "epidermal growth factor receptor (EGFR) family members are potential targets for therapy using extra-cellular domain receptor binding agents, such as the antibodies trastuzumab and cetuximab"}, {"qas": [{"id": "5313b049e3eabad021000013_004", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": " there were tendencies for upregulation of HER2, increased co-expression of EGFR and HER2 and downregulation of HER3 in the prostate cancer lymph node metastases in comparison to the primary tumors. "}, {"qas": [{"id": "5313b049e3eabad021000013_005", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "We performed a comparative analysis in vitro and in vivo of the antitumor effects of three different antibodies targeting different epitopes of ErbB2: Herceptin (trastuzumab), 2C4 (pertuzumab) and Erb-hcAb (human anti-ErbB2-compact antibody), a novel fully human compact antibody produced in our laboratory. Herein, we demonstrate that the growth of both androgen-dependent and independent prostate cancer cells was efficiently inhibited by Erb-hcAb. The antitumor effects induced by Erb-hcAb on some cell lines were more potent than those observed for either Herceptin or 2C4."}, {"qas": [{"id": "5313b049e3eabad021000013_006", "question": "Is the monoclonal antibody Trastuzumab (Herceptin) of potential use in the treatment of prostate cancer?", "is_impossible": false, "answers": "yes"}], "context": "These findings suggest that a systemic delivery of 212Pb-trastuzumab could             be an effective modality for management of advanced human prostate cancer."}]}]}